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1051-131 Combined Treatment With Epsilon Protein Kinase C 
Activator and Delta Protein Kinase C Inhibitor 
Ameliorates Ischemia Reperfusion Injury With 
Prolonged Ischemia in Rat Cardiac Allografts
Masashi Tanaka, Raya D. Terry, G. Kimia Mokhtari, E. Grant Hoyt, Tomoyoshi Koyanagi, 
Koichi Inagaki, Theo Kofidis, Daria Mochly-Rosen, Robert C. Robbins, Stanford 
University, Stanford, CA
Inhibition of delta protein kinase C (δPKC) and activation of epsilon PKC (εPKC) have
both been shown to limit damage from ischemia and reperfusion (I/R). Studies have per-
tained to ischemia or myocardial infarction in particular and have been conducted in cell
cultures, isolated rat heart models, or porcine models. However, whether these isozymes
can ameliorate I/R injury in the transplanted heart has not been determined. We investi-
gated the ability of PKC regulator to reduce I/R injury with prolonged ischemia in rat car-
diac allografts. Methods: Hearts of PVG rat (RT1c) were heterotopically transplanted into
ACI rats (RT1a). After cardioplegic arrest of the donor heart, the ascending aorta was
ligated, and 2 mL of εPKC activator (ψεRACK, 1.5 nmol) solution was then injected (ante-
grade coronary injection). Hearts were procured and submerged in the same drug solu-
tion (0.5 µM) for 30 or 120 min at 4°C. Before reperfusion, 1 ml of δPKC inhibitor (δV1-1,
30 nmol) solution was injected into the recipient IVC. Control animals were treated with
normal saline. Grafts were procured after 4 h of reperfusion (n = 6 each group) and ana-
lyzed for super oxide generation by the spin-trapping method; for myeloperoxidase
(MPO) activity, TNF-α, IL-1β, and MCP-1 production by ELISA; and for apoptosis by
TUNEL and by caspase-2, -3, -8, and -9 activities. Results: With 30-min ischemia, MPO
activity, TNF-α production, and caspase-9 activity decreased significantly in the PKC reg-
ulator-treated group. With 120 min-ischemia, MPO activity, TNF-α, IL-1β, MCP-1 produc-
tion, cardiomyocyte apoptosis, and caspase-2, -3 and -9 activities decreased significantly
in the PKC regulator-treated group. Super oxide generation and caspase-8 activity did
not differ significantly between the two groups with 30-min or 120-min ischemia. Conclu-
sions: Combined treatment with εPKC activator and δPKC inhibitor attenuates the I/R
injury that occurs with prolonged ischemia but does not suppress generation of super
oxide. This treatment inhibits the mitochondrial pathway on the induction of apoptosis.
These peptides may be useful in clinical transplantation for organ preservation and pre-
vention of I/R injury.
1051-132 S-Nitric Oxide-Human Serum Albumin, a Novel 
Intravenous Nitric Oxide-Donor, Minimizes I/R Injury 
After Four Hours of Ischemia in an Orthotopic Heart 
Transplant Model in the Pig
Roman Gottardi, Tomas Szerafin, Severin Semsroth, Harald Gasser, Seth Hallstroem, 
Rainald Seitelberger, Ernst Wolner, Bruno K. Podesser, University of Vienna, Vienna, 
Austria
BACKGROUND: In clinical heart transplantation the ischemic period tolerated by the
heart is still limited. Prolonged ischemia is associated with increased risk of acute and
chronic rejection. Depletion of nitric oxide (NO) is a major contributor to ischemia/reperfu-
sion (I/R) injury. We hypothesize that NO-substitution with S-Nitroso Human Serum Albu-
min (S-NO-HSA), a new physiologic NO-donor, could bridge NO-starvation during I/R
and improve hemodynamic outcome in a model of orthotopic heart transplantation in the
pig.
METHODS: Donor pigs (n=19; 37,1±6,1 kg) were monitored and randomized to treat-
ment with (1µmol/kg/h) S-NO-HSA (n=11) or HSA (n=8; control) one hour prior to explan-
tation. Hearts were harvested and stored using Bretschneider solution with addition of
10µmol/L S-NO-HSA or HSA respectively (4°C for 4 hours). Recipient pigs (n=19;
36.5±5,9 kg) were monitored and put on cardiopulmonary bypass (CPB). Donor hearts
were implanted followed by 60 min of controlled reperfusion before subsequent weaning
from CPB (epinephrine 0,4 µ/kg/h) and a follow up of two hours. Thirty min prior to esti-
mated aortic declamping, infusion with S-NO-HSA or HSA respectively started for 60 min
(0,1 µmol/kg/h).
RESULTS: At the end of S-NO-HSA infusion in donors , a decrease in heartrate, mean
arterial pressure, left ventricular systolic pressure (LVP sys) and Wedge pressure com-
pared to control was observed. During the first 15min of reperfusion, coronary flow/car-
diac output per kg bodyweight was significantly higher in the S-NO-HSA versus the HSA
group (p<0.01). During the entire follow up there was a lower wedge pressure in the treat-
ment group that reached significance after 60 min (p<0.05). LVP sys was significantly
higher in the treatment group 30 min after weaning from CPB (p<0.05) and became
highly significant after 75 min (p<0.01).
CONCLUSIONS: In a pig model of orthotopic heart transplantation with 4 hours of
ischemia S-NO-HSA significantly minimizes I/R injury and improves organ function as
shown by an improvement of myocardial perfusion during early reperfusion, a lower
wedge pressure, indicating a better diastolic function, and a better systolic function after
weaning from CPB in the S-NO-HSA group.
1051-133 Localized Combinatorial Interleukin-4 and Interleukin-10 
Gene Therapy Readjusts the Balance of Endogenous 
Th1/Th2 Cytokines and Induces the Tolerance of 
Cardiac Allografs
Hiroshi Furukawa, Kiyohiro Oshima, Thomas C. Tung, Hyde Russell, Guanggen Cui, 
Hillel Laks, Luyi Sen, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA
The balance of Th1/Th2 cytokine plays an important role in the allograft tolerance, how-
ever, its operating mechanism remains unknown. Using a functional cervical heterotopic
rabbit heart transplant model, we tested the hypothesis that liposome-mediated ex vivo
intracoronary interleukin-4 (IL-4) and IL-10 combined gene therapy may induce localized
IL-4 and IL-10 over expression that may synergistically regulates endogenous Th1/Th2
expression, which may contributes the allograft tolerance. The mean survival of cardiac
allograft was prolonged from 7± 1 days in Control Group (CG) to 14±3 days in IL-4 gene
therapy group (IL-4G), 28± 7 days in IL-10 gene therapy Group (IL-10G) and 135± 20
days in IL-4 and IL-10 combined gene therapy Group (IL-4&10G). The transgene and
exogenous protein expression in IL-4&10G reached the peak in postoperative day (POD)
5-8, and slowly reduced thereafter. The rejection score in IL-4&10G (n=15) was signifi-
cantly lower (2.2± 0.2, p<0.05) than that of CG (3.6± 0.2, n=15) and IL-10G (2.7± 0.3,
n=15) in POD3-6, and 2.0± 0.0 in POD>31. In single cytokine gene therapy caused an
excessive localized exogenous cytokine gene and protein expression which significantly
downregulated the expression of the same endogenous cytokine, IL-4 or IL-10 gene
(p<0.01), but in a certain extent upregulated the other Th2 cytokine genes expression
(p<0.01). In IL-4&10G, endogenous IL-4 and IL-10 gene expression was decreased in
the early stage, then increased at POD 18-20 and remained in a high level for a long
period of time. The expression of Th1 cytokine genes, IL-1β and TNF-α , were signifi-
cantly decreased by the synergistic inhibition of IL-4 and IL-10, and maintained in the low
level in the late stage. IFN-γ gene expression level was increased in IL-4G, decreased in
IL-10G. The slightly decreased IFN-γ gene expression level observed in the combined
gene therapy group that could be resulted from antagonistic immunoregulatory effects of
two cytokines. We conclude that localized overexpression of exogenous IL-4 and IL-10
induced by ex vivo gene transfer could act synergistically for readjusting the balance of
endogenous Th1/Th2 cytokines that may contribute to the allograft tolerance.
1051-134 Downregulation of Connexin 43 Expression in Chronic 
Cardiac Allograft Rejection
Lathasree Polavaram, Daniel Zaghi, Guanggen Cui, Hardeep Singh Ahluwalia, Luyi Sen, 
UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA
Down-regulation of the major gap-junctional protein of the ventricular myocytes,
Connexin43 (Cx43), has previously been reported in heart failure due to ischemic dilated
Cardiomyopathy (ICM) and idiopathic dilated cardiomyopathy (DCM). However, whether
it is also altered in chronic cardiac allograft rejection remains unknown. In this study, left
ventricle samples from 40 patients with dilated cardiomyopathy and end-stage heart fail-
ure underwent heart transplantation were analyzed for Cx43 and Cx40 using Western
blot analysis. Fourteen patients had DCM, 12 had ICM and 14 had chronic cardiac
allograft rejection underwent re-transplantation (CAR). Actin antibody was used as an
internal control. Left ventricular samples from 6 donor hearts were used as normal con-
trol (NLC). Cx43 expression level was significantly decreased in CAR group (0.68±0.31)
compared with that in NLC (1.14±0.49, p=0.019). The down-regulation of Cx43 was also
observed in ICM (0.73±0.36, p=0.057). In DCM, Cx43 expression level was only slightly
decreased (0.85±0.32, p=0.1205). Cx40 expression was slightly increased in CAR, ICM
and DCM compared with that in NLC (p=0.14, p=0.14 and p=0.22 respectively). All the 3
groups showed increased Pulmonary Capillary Wedge Pressure (DCM: 19.92±10.82,
ICM: 22.88±10.34, CAR: 18±7), Right Atrial Pressure (DCM: 8.5±3.17, ICM: 10.11±5.77,
CAR: 13.7±5.5). ICM and DCM in addition had increased Left Ventricular End Diastolic
Diameter (LVEDD) and decreased Left Ventricular Ejection Fraction (LVEF). The
decrease of LVEDD and LVEF in CAR was only mild to moderate. There is no significant
correlation between Cx43 and LVEDD and LVEF (p>0.05). In conclusion, these results
suggest that the altered connexin expression in ventricular tissue may be related to the
inflammation in ischemic cardiomyopathy and CAR. The down-regulation of Cx43 might
be responsible for the alteration of electrical excitation and conduction in myocardium,
but may not play a major role in the hemodynamics in both ICM and CAR.
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1068-121 Impact of Myocardial Viability Assessment on the 
Beneficial Effect of Cardiac Resynchronization Therapy 
in Patients With Ischemic Cardiomyopathy
Jacopo Dalle Mule, Renzo Perelli, Marco Mazzella, Felice Martinelli, Alessandro 
Proclemer, Virginia Scarabeo, Maria Liberata Di Sipio, City Hospital Pieve di Cadore 
Cortina Auronzo, Pieve di Cadore Cortina, Italy, Ospedale San Martino, Belluno, Italy
Background we hypothesized that imaging with Thallium201 imaging for viability could
help identify patients with ischemic left ventricular (LV) systolic dysfunction under opti-
mized medical treatment and dyssynchrony who benefit from cardiac resynchronization
therapy (CRT)
Methods: we assessed viability status in 45 consecutive patients (age 64 ±7 y.o.) with LV
EF <= 35%, QRS >= 120 ms, NYHA class 3 or 4, using SPECT Thallium201 stress, early
and 24-h redistribution imaging with a 20-segment model before CRT with biventricular
pacing (BiV), measured EF, inter- and intra-ventricular synchrony conduction delay with
gated radionuclide ventriculography , LV End Diastolic Volume Indices (LVEDVI) with
echocardiography before and 6 months after BiV
Results: 
Patients with <= 5 scarred segments on Thallium201 imaging (Group A) demonstrated
improvement of LVEF at 6 months (from 29 ±5% to 36 ±5%, p<0.0001), 21/23 (91%) had
an EF increase >5 units, NYHA class (from 3.3 ±0.5 to 2.5 ±0.5, p<0.0001), reverse
remodelling (LVEDVI decreased from 99 ±17 ml/m2 to 86 ±16 ml/m2, p<0.0001).
Conversely, patients with >5 scarred segments (Group B) failed to improve in LVEF (30
